June25, 2009
Skinvisible Receives Comprehensive Patent in China:
LAS VEGAS, Nevada. June 25, 2009 - Skinvisible, Inc. (OTC Bulletin Board: SKVI / Website: www.skinvisible.com), is pleased to announce that it has been granted a comprehensive patent in China for Invisicare; Skinvisible's polymer delivery system that enhances topically delivered products. This patent covers the areas of 'Topical Composition', 'Topical Composition Precursor', and 'Methods for Manufacturing and Using'.
This patent in China will assist Skinvisible in solidifying on-going negotiations with potential licensees and to continue to expand its offerings into Asia. Receiving a patent that contains all three key components, gives potential licensees the protection needed to begin marketing products in China. Skinvisible continues to make advances in China with potential licensees for its products; most notably with its DermSafe® hand sanitizer made without alcohol and proven to kill/inactivate the H1N1 virus.
"Receiving this patent in China gives Skinvisible a great advantage in the Asian marketplace," said Mr. Terry Howlett, President and CEO of Skinvisible. "We know how important patent protection is for our potential licensees, so we continue to gain advantages as more of our patents are granted. Patent protection increases the value of Skinvisible formulations and allows licensees the security they seek when in-licensing our topical dermatology products. We continue to receive patent approvals around the globe, solidifying Invisicare's protected position worldwide."
Along with its patent protection, Invisicare adds a number of key advantages to topical products. Potential licensees look for life cycle management solutions to extend the life of their products coming off patent and look for product benefits that will differentiate their products in the highly competitive dermatology, consumer goods and medical markets. Invisicare provides this by adding the unique ability to hold active ingredients on the skin for extended periods of time while resisting wash-off, rub-off and perspiration. It also enhances topical skincare products by controlling the release of active ingredients; allowing for less active to be used with the same or better results.
In conjunction with this patent announcement, Skinvisible is pleased to announce that it was selected by the US Chamber of Commerce as one of the one hundred companies from across the United States to be profiled in their "Faces of IP" project. This project is scheduled to be launched in July of this year. The mission of this project is to "champion intellectual property as vital to creating jobs, saving lives, advancing global economic growth, and generating breakthrough solutions to global challenges." Skinvisible has made, and continues to make substantial investments into the protection of its intellectual property worldwide. Invisicare along with formulations developed by Skinvisible with its technology, have patent protection or patents pending internationally. Along with two US patents, Skinvisible has been granted patents in India, Australia, Japan and now China.
About Invisicare®
Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. www.skinvisible.com
|
Skinvisible Web
Click here